Belzutifan is a novel oral anticancer agent that inhibits hypoxia-inducible factor-2α (HIF-2α) and is associated with characteristic adverse events, including anemia and hypoxia. This study evaluated the incidence and clinical course of adverse events in patients who received belzutifan therapy in an outpatient setting, with a particular focus on hypoxia.
No takes yet. Share an insight, caveat, or question.
Takahashi-Matsuyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: